灯盏生脉胶囊联合西药治疗冠心病合并慢性心力衰竭临床研究  

Clinical Study on Dengzhan Shengmai Capsules Combined with Western Medicine for Coronary Heart Disease Complicated with Chronic Heart Failure

作　　者：吴淑女 WU Shunv(Lishui Hospital of Traditional Chinese Medicine,Lishui Zhejiang 323000,China)

机构地区：[1]丽水市中医院,浙江丽水323000

出　　处：《新中医》2024年第6期47-51,共5页New Chinese Medicine

摘　　要：目的:观察灯盏生脉胶囊联合西药治疗冠心病(CHD)合并慢性心力衰竭(CHF)气阴两虚证的临床疗效。方法:选取92例CHD合并CHF气阴两虚证患者,以随机数字表法分为对照组和治疗组各46例。对照组给予盐酸曲美他嗪片、酒石酸美托洛尔片治疗,治疗组在对照组基础上给予灯盏生脉胶囊治疗,2组均治疗1个月。对比2组临床疗效、中医证候积分、超声心动图指标[左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)]及实验室指标[N末端B型利钠肽前体(NT-proBNP)、脂联素(APN)、基质金属蛋白酶-9(MMP-9)]。结果:治疗后,治疗组总有效率95.65%,高于对照组80.43%(P<0.05)。2组中医证候积分均较治疗前降低(P<0.05),治疗组中医证候积分低于对照组(P<0.05)。2组LVEDD、LVESD均较治疗前减小(P<0.05),治疗组LVEDD、LVESD均小于对照组(P<0.05)。2组LVEF均较治疗前升高(P<0.05),治疗组LVEF高于对照组(P<0.05)。2组血清NT-proBNP、MMP-9水平均较治疗前降低(P<0.05),治疗组血清NT-proBNP、MMP-9水平均低于对照组(P<0.05)。2组血清APN水平均较治疗前升高(P<0.05),治疗组血清APN水平高于对照组(P<0.05)。结论:在西药基础上加用灯盏生脉胶囊治疗CHD合并CHF气阴两虚证可提升临床疗效,有效缓解症状及改善心功能,作用机制可能与调节血清NT-proBNP、MMP-9、APN水平有关。Objective:To observe the clinical effect of Dengzhan Shengmai Capsules combined with western medicine on coronary heart disease(CHD)complicated with chronic heart failure(CHF)with dual deficiency of qi and yin syndrome.Methods:A total of 92 cases of patients with CHD complicated with CHF with dual deficiency of qi and yin syndrome were divided into the control group and the treatment group according to the random number table method,with 46 cases in each group.The control group was treated with Trimetazidine Hydrochloride Tablets and Metoprolol Tartrate Tablets,and the treatment group Was additionally treated with Dengzhan Shengmai Capsules based on the treatment of the control group.Both groups were treated for 1 month.The clinical effects,traditional Chinese medicine(TCM)syndrome scores,echocardiogram indexes[left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)and left ventricular ejection fraction(LVEF)],and laboratory indexes[N-terminal B-type natriuretic peptide precursor(NT-proBNP),adiponectin(APN)and matrix metalloproteinase-9(MMP-9)]were compared between the two groups.Results:After treatment,the total effective rate was 95.65%in the treatment group,higher than that of 80.43%in the control group(P<0.05).The TCM syndrome scores in the two groups were decreased when compared with those before treatment(P<0.05),and the TCM syndrome score in the treatment group was lower than that in the control group(P<0.05).LVEDD and LVESD in the two groups were decreased when compared with those before treatment(P<0.05),and LVEDD and LVESD in the treatment group Were lower than those in the control group(P<0.05).LVEF in the two groups were increased when compared with those before treatment(P<0.05),and LVEF in the treatment group Was higher than that in the control group(P<0.05).The levels of NT-proBNP and MMP-9 in serum in the the two groups were decreased when compared with those before treatment(P<0.05),and the levels of NT-proBNP and MMP-9 in serum in the treatment group were low

关 键 词：冠心病 慢性心力衰竭 气阴两虚证 灯盏生脉胶囊 盐酸曲美他嗪片 酒石酸美托洛尔片 心功能 

分 类 号：R541[医药卫生—心血管疾病]